Prague Med. Rep. 2023, 124, 5-15
https://doi.org/10.14712/23362936.2023.1
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
References
1. , A., Alsantali, A., Wang, E., McElwee, K. J., Shapiro, J. (2010) Alopecia areata update: Part II. Treatment. J. Am. Acad. Dermatol. 62(2), 191–204.
<https://doi.org/10.1016/j.jaad.2009.10.031>
2. , A., Wang, E., Lee, E. Y., Aoki, V., Christiano, A. M. (2019) Pathomechanisms of immune-mediated alopecia. Int. Immunol. 31(7), 439–447.
<https://doi.org/10.1093/intimm/dxz039>
3. , C., Deniro, K., Brichta, L., Craiglow, B. G., Sidbury, R. (2017) Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J. Am. Acad. Dermatol. 77(1), 167–170.
<https://doi.org/10.1016/j.jaad.2017.03.024>
4. ClinicalTrials.gov (2022) Long-term PF-06651600 for the treatment of alopecia areata (ALLEGRO-LT). Accessed June 25, 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT04006457
5. , B., King, B. (2014) Killing two birds with one stone: Oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Invest. Dermatol. 134(12), 2988–2990.
<https://doi.org/10.1038/jid.2014.260>
6. , E., Hirt, P. A., Fertig, R., Doliner, B., Delcanto, G., Jimenez, J. J. (2018) Alopecia areata: Review of epidemiology, clinical features, pathogenesis, and new treatment options. Int. J. Trichology 10(2), 51–60.
<https://doi.org/10.4103/ijt.ijt_99_17>
7. , K. L. (2021) A comprehensive literature review of JAK inhibitors in treatment of alopecia areata. Clin. Cosmet. Investig. Dermatol. 25(14), 691–714.
<https://doi.org/10.2147/CCID.S309215>
8. European Medicines Agency (2017) Olumiant. Updated June 29, 2022. Accessed August 26, 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant
9. European Medicines Agency (2017) Xeljanz. Updated July 8, 2022. Accessed September 5, 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz
10. , G., McInnes, I., Siebert, S. (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 58, i43–i54 (Suppl. 1).
<https://doi.org/10.1093/rheumatology/key276>
11. , C., Finkel, M., Christos, P. J., Sinha, A. A. (2006) Profile of 513 patients with alopecia areata: Associations of disease subtypes with atopy, autoimmune disease and positive family history. J. Eur. Acad. Dermatol. Venereol. 20(9), 1055–1060.
<https://doi.org/10.1111/j.1468-3083.2006.01676.x>
12. , L., Lebrun-Vignes, B., Maury, S., Mahevas, M., Karoui, K. E., Roy, L., Zarour, A., Michel, M., Cohen, J. L., Amiot, A., Claudepierre, P., Wolkenstein, P., Grimbert, P., Sbidian, E. (2022) Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep. 12(1), 7140.
<https://doi.org/10.1038/s41598-022-10777-w>
13. , A., Sansarcq, F., Cerise, J., Chen, J. J., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., Mackay-Wiggan, J. (2018) An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch type alopecia areata, totalis, and universalis. J. Invest. Dermatol. 138(7), 1539–1545.
<https://doi.org/10.1016/j.jid.2018.01.032>
14. , S. C., Tabbara, N., Burry, L. (2022) A review of COVID-19 therapeutics in pregnancy and lactation. Obstet. Med. 15(4), 225–232.
<https://doi.org/10.1177/1753495X211056211>
15. , C. M., Ko, J., Craiglow, B., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C., Marinkovich, M. P., Christiano, A. M., Oro, A. E., King, B. A. (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1(15), e89776.
16. , A., Smolen, J. S., Nash, P., Doerner, T., Dougados, M., Fleischmann, R., Geissler, K., McInnes, I. B., Takeuchi, T., Trauner, M., Winthrop, K., de Wit, M., Boehncke, W. H., Falzon, L., van der Heijde, D. (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A systematic literature research. RMD Open 6(3), e001374.
<https://doi.org/10.1136/rmdopen-2020-001374>
17. , B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W. S., McCollam, J., Chiasserini, C., Yu, G., Stanley, S., Holzwarth, K., DeLozier, A. M., Sinclair, R.; BRAVE-AA Investigators (2022) Two phase 3 trials of baricitinib for alopecia areata. N. Engl. J. Med. 386(18), 1687–1699.
<https://doi.org/10.1056/NEJMoa2110343>
18. , E., Aslam, N., Nigam, G., Limdi, J. K. (2022) Tofacitinib and newer JAK inhibitors in inflammatory bowel disease – Where we are and where we are going. Drugs Context 11, 2021-11-4.
<https://doi.org/10.7573/dic.2021-11-4>
19. , L. Y., Craiglow, B. G., Dai, F., King, B. A. (2017) Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J. Am. Acad. Dermatol. 76(1), 22–28.
<https://doi.org/10.1016/j.jaad.2016.09.007>
20. , L. Y., Craiglow, B. G., King, B. A. (2018) Tofacitinib 2% ointment, a topical Janus kinase inhibitor for the treatment of alopecia areata: A pilot study of 10 patients. J. Am. Acad. Dermatol. 78(2), 403–404.
<https://doi.org/10.1016/j.jaad.2017.10.043>
21. , C., Jairath, V., Vande Casteele, N. (2019) Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease. Best Pract. Res. Clin. Gastroenterol. 38–39, 101606.
<https://doi.org/10.1016/j.bpg.2019.03.002>
22. , J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., Clynes, R. (2016) Oral ruxolitinib induces hair-growth in patients with moderate-severe alopecia areata. JCI Insight 1(15), e89790.
<https://doi.org/10.1172/jci.insight.89790>
23. National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 44205240, Baricitinib. Accessed November 27, 2022. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Baricitinib
24. National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 25126798, Ruxolitinib. Accessed November 27, 2022. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib
25. National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 9926791, Tofacitinib. Accessed November 27, 2022. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Tofacitinib
26. , M. (2018) What is behind the “swarm of bees” in alopecia areata. Br. J. Dermatol. 179(5), 1023–1024.
<https://doi.org/10.1111/bjd.17142>
27. , E. A., Kornacki, D., Sun, K., Hordinsky, M. K. (2020) Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J. Am. Acad. Dermatol. 82(2), 412–419.
<https://doi.org/10.1016/j.jaad.2019.10.016>
28. , R., Ito, N., Takigawa, M., Ito, T. (2003) The hair follicle and immune privilege. J. Investig. Dermatol. Symp. Proc. 8(2), 188–194.
<https://doi.org/10.1046/j.1087-0024.2003.00807.x>
29. Pfizer (2021) Pfizer announces positive top-line results from phase 2b/3 trial of ritlecitinib in alopecia areata. Press release. Accessed June 20, 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-2b3-trial
30. , H. A., Tosti, A. (2022) Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des. Devel. Ther. 16, 363–374.
<https://doi.org/10.2147/DDDT.S334727>
31. , Y., Spolski, R., Leonard, W. J. (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9(7), 480–490.
<https://doi.org/10.1038/nri2580>
32. , J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., Yeleswaram, S. (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J. Clin. Pharmacol. 54(12), 1354–1361.
<https://doi.org/10.1002/jcph.354>
33. , K., Suchonwanit, P. (2018) Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des. Devel. Ther. 12, 2323–2335.
<https://doi.org/10.2147/DDDT.S172638>
34. , R., Dutra, H., Dias, M. (2018) A comment on JAK inhibitors for treatment of alopecia areata. Int. J. Trichology 10(5), 193–197.
<https://doi.org/10.4103/ijt.ijt_62_18>
35. U.S. Food and Drug Administration (2022) FDA Approves First Systemic Treatment for Alopecia Areata. Released June 13, 2022. Updated June 13, 2022. Accessed June 22, 2022. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
36. Fricke, A. C., Miteva, M. (2015) Epidemiology and burden of alopecia areata: A systematic review. Clin. Cosmet. Investig. Dermatol. 8, 397–403.
37. , A., Rakowska, A., Sikora, M., Olszewska, M., Rudnicka, L. (2018) Trichoscopy of alopecia areata: An update. J. Dermatol. 45(6), 692–700.
<https://doi.org/10.1111/1346-8138.14283>
38. , R., Banerjee, A., Sikirica, V., Peeva, E., Wyrwich, K. (2022) Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib. J. Eur. Acad. Dermatol. Venereol. 36(4), 602–609.
<https://doi.org/10.1111/jdv.17909>
39. , C., Li, X., Wang, C., Zhang, J. (2021) Alopecia areata: An update on etiopathogenesis, diagnosis, and management. Clin. Rev. Allergy Immunol. 61, 403–423.
<https://doi.org/10.1007/s12016-021-08883-0>
